The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles, and represent a growing area of global development focus, for applications such as oncology and hormone-based treatments. Although this class of molecules offers numerous benefits to patients, they require particular care and attention in ensuring the safety for those involved in their manufacture and handling.
Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.
Leading global supplier of materials, Goodfellow, has collaborated with a number of major international companies to provide research materials in several industry sectors.
DIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.
BioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.
In March, the 9th edition of the "European Biotechnology Science & Industry Guide" will be published and distributed at BIO Europe Spring conference 2019 in Vienna. The B2B handbook presents companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing an ideal medium with which new customers and investors can find you. The previous edition can be found here.
Medigene is developing the next generation of effective TCR cell therapies aimed at establishing better control over cancer at reasonable production cost.
CYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.
Vetter strikes out on new pathways to further develop the injection process.
CDMO launches the Vetter Open Innovation Challenge under the slogan Injection 2.0